ZTSZoetis

Health care · Pharmaceuticals · NYSE

Employees: 14,500
Headquarters: Parsippany, NJ
CEO: Kristin C. Peck
Next results: around Feb 11, 2027

The numbers ZTS said it expected, in its earnings releases of the last 3 years, next to what it then reported for the same period. Each target links to the sentence in the release; each result to the 10-Q or 10-K it was first reported in.

Of 6 range targets with a reported result: 2 came in above the last range given, 4 within it, 0 below it.

Target	What the company said	Reported	Result
Net income Fiscal 2026	Given $2.83B to $2.88B release 2026-02-12	–	Not reported yet
The company's words Zoetis is providing full year 2026 guidance as follows: … Reported net income between $2.825 billion to $2.875 billion release 2026-02-12
Net income (company-defined) Fiscal 2026	Given $2.98B to $3.02B release 2026-02-12	–	No standard number
The company's words Zoetis is providing full year 2026 guidance as follows: … Adjusted net income between $2.975 billion to $3.025 billion ( organic operational growth of 3% to 6%) release 2026-02-12
Diluted EPS Fiscal 2026	Given $6.65 to $6.75 release 2026-02-12	–	Not reported yet
The company's words Zoetis is providing full year 2026 guidance as follows: … Reported diluted EPS between $6.65 to $6.75 release 2026-02-12
Diluted EPS (company-defined) Fiscal 2026	Given $7.00 to $7.10 release 2026-02-12	–	No standard number
The company's words Zoetis is providing full year 2026 guidance as follows: … Adjusted diluted EPS between $7.00 to $7.10 release 2026-02-12
Revenue Fiscal 2026	Given $9.82B to $10.03B release 2026-02-12 Lowered $9.68B to $9.96B release 2026-05-07 Lowered $9.12B to $9.32B release 2026-08-06	–	Not reported yet
The company's words Zoetis is providing full year 2026 guidance as follows: … Revenue between $9.825 billion to $10.025 billion ( organic operational growth of 3% to 5%) release 2026-02-12 Revises Full Year 2026 Revenue Guidance to $9.680 - $9.960 Billion with Organic Operational Revenue Growth of 2% to 5% release 2026-05-07 Revises Full Year 2026 Revenue Guidance to $9.120 - $9.320 Billion to Organic Operational Revenue Growth of (3)% to (1)% release 2026-08-06
Net income Fiscal 2025 (ended 2025-12-31)	Given $2.57B to $2.62B release 2025-02-13 Raised $2.63B to $2.68B release 2025-05-06	$2.67B 10-K filed 2026-02-12	Within the range
The company's words Zoetis is providing full year 2025 guidance, which includes: … Reported net income between $2.570 billion to $2.620 billion release 2025-02-13 Zoetis is updating its full year 2025 guidance. … Reported net income between $2.630 billion to $2.680 billion release 2025-05-06
Net income (company-defined) Fiscal 2025 (ended 2025-12-31)	Given $2.70B to $2.75B release 2025-02-13 Raised $2.77B to $2.83B release 2025-05-06	–	No standard number
The company's words Zoetis is providing full year 2025 guidance, which includes: … Adjusted net income between $2.700 billion to $2.750 billion ( operational growth of 2% to 4%; organic operational growth of 6% to 8%) release 2025-02-13 Zoetis is updating its full year 2025 guidance. … Adjusted net income between $2.775 billion to $2.825 billion (organic operational growth of 5% to 7% ) release 2025-05-06
Diluted EPS Fiscal 2025 (ended 2025-12-31)	Given $5.70 to $5.80 release 2025-02-13 Raised $5.85 to $5.95 release 2025-05-06	$6.02 10-K filed 2026-02-12	Above the range
The company's words Zoetis is providing full year 2025 guidance, which includes: … Reported diluted EPS between $5.70 to $5.80 release 2025-02-13 Zoetis is updating its full year 2025 guidance. … Reported diluted EPS of $5.85 to $5.95 release 2025-05-06
Diluted EPS (company-defined) Fiscal 2025 (ended 2025-12-31)	Given $6.00 to $6.10 release 2025-02-13 Raised $6.20 to $6.30 release 2025-05-06 Raised $6.30 to $6.40 release 2025-08-05	–	No standard number
The company's words Zoetis is providing full year 2025 guidance, which includes: … Adjusted diluted EPS between $6.00 to $6.10 release 2025-02-13 Zoetis is updating its full year 2025 guidance. … Adjusted diluted EPS between $6.20 to $6.30 release 2025-05-06 Raises Full Year 2025 Outlook … Raises Guidance for Diluted EPS on an Adjusted Basis to $6.30 to $6.40 release 2025-08-05
Revenue Fiscal 2025 (ended 2025-12-31)	Given $9.22B to $9.38B release 2025-02-13 Raised $9.43B to $9.57B release 2025-05-06 Raised $9.45B to $9.60B release 2025-08-05 Lowered $9.40B to $9.47B release 2025-11-04	$9.47B 10-K filed 2026-02-12	Within the range
The company's words Zoetis is providing full year 2025 guidance, which includes: … Revenue between $9.225 billion to $9.375 billion ( operational growth of 2% to 4%; organic operational growth of 6% to 8%) release 2025-02-13 Updates Full Year 2025 Revenue Guidance to $9.425 - $9.575 Billion to Reflect the Impact of Foreign Exchange and Maintains Guidance for Organic Operational Revenue Growth of 6% to 8% release 2025-05-06 Raises Full Year 2025 Revenue Guidance to $9.450 - $9.600 Billion with Organic Operational Revenue Growth of 6.5% to 8.0% Following Strong First-Half Performance release 2025-08-05 Revises Full Year 2025 Revenue Guidance to $9.400 - $9.475 Billion with Organic Operational Revenue Growth of 5.5% to 6.5% Based on Broader Macro Trends and the Operational Environment release 2025-11-04
Net income Fiscal 2024 (ended 2024-12-31)	Given $2.47B to $2.51B release 2024-02-13	$2.49B 10-K filed 2025-02-13	Within the range
The company's words Zoetis is providing full year 2024 guidance, which includes: … Reported net income between $2.468 billion to $2.513 billion release 2024-02-13
Net income (company-defined) Fiscal 2024 (ended 2024-12-31)	Given $2.65B to $2.70B release 2024-02-13	–	No standard number
The company's words Zoetis is providing full year 2024 guidance, which includes: … Adjusted net income between $2.650 billion to $2.700 billion ( operational growth of 9% to 11%) release 2024-02-13
Diluted EPS Fiscal 2024 (ended 2024-12-31)	Given $5.34 to $5.44 release 2024-02-13	$5.47 10-K filed 2025-02-13	Above the range
The company's words Provides Full Year 2024 Revenue Guidance of $9.075 - $9.225 Billion, with Diluted EPS of $5.34 to $5.44 release 2024-02-13
Diluted EPS (company-defined) Fiscal 2024 (ended 2024-12-31)	Given $5.74 to $5.84 release 2024-02-13 Raised $5.86 to $5.92 release 2024-11-04	–	No standard number
The company's words Zoetis is providing full year 2024 guidance, which includes: … Adjusted diluted EPS between $5.74 to $5.84 release 2024-02-13 Raises Full Year 2024 Revenue Guidance to $9.200 - $9.300 Billion, Representing Operational Revenue Growth of 10% to 11%, with Diluted EPS on an Adjusted Basis of $5.86 to $5.92 release 2024-11-04
Revenue Fiscal 2024 (ended 2024-12-31)	Given $9.07B to $9.22B release 2024-02-13 Raised $9.20B to $9.30B release 2024-11-04	$9.26B 10-K filed 2025-02-13	Within the range
The company's words Provides Full Year 2024 Revenue Guidance of $9.075 - $9.225 Billion, with Diluted EPS of $5.34 to $5.44 release 2024-02-13 Raises Full Year 2024 Revenue Guidance to $9.200 - $9.300 Billion, Representing Operational Revenue Growth of 10% to 11%, with Diluted EPS on an Adjusted Basis of $5.86 to $5.92 release 2024-11-04

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (13 releases since 2023-11-02), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Work on ZTS in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/ZTS/export.csv") into a cell.